As part of the MAT Expansion efforts combating the opioid crisis across the state of California, UCLA launched a new training initiative to provide customized technical assistance specifically to support and expand the impact of waivered prescribers to treat patients struggling with opioid use disorder. The objective of the MAT Waivered Prescriber Support Initiative is to identify the barriers to prescribing buprenorphine and provide the targeted mentorship, training, and technical assistance to address those barriers. Prescribers will connect with experienced buprenorphine providers throughout California to access direct consultation. Services offered may include direct mentorship by phone or video, on-site or off-site TA (e.g., program/provider visits, prescriber shadowing), and in-person or virtual training activities related to treating patients with OUD.
Featured Speaker: Dennis A. Wichern
Description: This one-hour web training will provide an overview of the authority of the Drug Enforcement Administration (DEA), Food and Drug Administration (FDA), and Substance Abuse and Mental Health Services Administration (SAMHSA) as it relates to regulating the use of medications in the provision of treatment for opioid use disorders (OUD), along with a review of national studies, risk mitigation strategies, case studies, emerging issues, commonly asked questions, and strategies for preventing a DEA audit. The goal of the training session is to alleviate provider concerns relative to operating a MAT medical practice.
Save the Date: December 16, 2019, 12-1PM. Registration will be open soon.
Continuing Medical Education and Continuing Education (CME/CE) credit offered at no cost!
For more information, contact Cfrable@mednet.ucla.edu